- Home
- VALU vs NGNE Comparison
VALU vs NGNE Comparison
Compare VALU & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- NGNE
- Stock Information
- Founded
- VALU 1931
- NGNE 2003
- Country
- VALU United States
- NGNE United States
- Employees
- VALU N/A
- NGNE N/A
- Industry
- VALU Investment Managers
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- NGNE Health Care
- Exchange
- VALU Nasdaq
- NGNE Nasdaq
- Market Cap
- VALU 345.7M
- NGNE 325.3M
- IPO Year
- VALU N/A
- NGNE N/A
- Fundamental
- Price
- VALU $38.85
- NGNE $17.71
- Analyst Decision
- VALU
- NGNE Strong Buy
- Analyst Count
- VALU 0
- NGNE 7
- Target Price
- VALU N/A
- NGNE $41.86
- AVG Volume (30 Days)
- VALU 6.6K
- NGNE 133.6K
- Earning Date
- VALU 09-15-2025
- NGNE 11-14-2025
- Dividend Yield
- VALU 3.40%
- NGNE N/A
- EPS Growth
- VALU 6.17
- NGNE N/A
- EPS
- VALU 2.26
- NGNE N/A
- Revenue
- VALU $34,801,000.00
- NGNE N/A
- Revenue This Year
- VALU N/A
- NGNE N/A
- Revenue Next Year
- VALU N/A
- NGNE N/A
- P/E Ratio
- VALU $16.95
- NGNE N/A
- Revenue Growth
- VALU N/A
- NGNE N/A
- 52 Week Low
- VALU $32.94
- NGNE $6.88
- 52 Week High
- VALU $57.68
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- VALU 54.85
- NGNE 38.90
- Support Level
- VALU $37.95
- NGNE $17.13
- Resistance Level
- VALU $38.84
- NGNE $20.72
- Average True Range (ATR)
- VALU 0.75
- NGNE 1.29
- MACD
- VALU 0.10
- NGNE -0.18
- Stochastic Oscillator
- VALU 86.30
- NGNE 16.20
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.